Literature DB >> 6769527

Behavioural changes induced by N,N-dimethyl-tryptamine in rodents.

P Jenner, C D Marsden, C M Thanki.   

Abstract

1 N,N-Dimethyltryptamine (DMT) in pargyline pretreated rodents induced a dose-dependent behavioural syndrome consisting of hyperactivity, prostration and hindlimb abduction, mild tremor, Straub tail, retropulsion and jerking. 2 In rats pretreated with pargyline, the behavioural syndrome induced by DMT differed from that induced by L-tryptophan or quipazine, in the lack of forepaw treading and head-weaving and in the presence of only mild tremor. 3 The hyperactivity component of the DMT-induced behavioural syndrome in pargyline-pretreated mice was potentiated by cyproheptadine, methergoline, and mianserin, inhibited by cinanserin, haloperidol, pimozide, methiothepin and propranolol, and not affected by 501C67-sulphate and methysergide. 4 The maximal behavioural changes induced by DMT in rats, other than hyperactivity, were unaffected by pretreatment with cyproheptadine, methysergide, and cinanserin. However, propranolol reduced the intensity of all behavioural effects apart from body jerking, and methergoline decreased the duration of prostration. Phenoxybenzamine and haloperidol, in contrast, enhanced prostration. 5 DMT plus pargyline did not induce circling behaviour in mice with a unilateral 6-hydroxy-dopamine lesion of the nigro-striatal pathway. 6 The DMT-induced behavioural syndrome appears to consist of two components, (a) hyperactivity and (b) other behavioural changes. They differ in their response to drugs affecting brain monoamines. The hyperactivity component may be expressed via dopamine mechanisms, but the other behavioural changes are not. The two behaviours do not respond consistently to drugs believed to alter brain 5-hydroxytryptamine function.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6769527      PMCID: PMC2044189          DOI: 10.1111/j.1476-5381.1980.tb10884.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  40 in total

1.  Hallucinogen binding to dopamine/neuroleptic receptors.

Authors:  P M Whitaker; P Seeman
Journal:  J Pharm Pharmacol       Date:  1977-08       Impact factor: 3.765

2.  Direct evidence for an interaction of beta-adrenergic blockers with the 5-HT receptor.

Authors: 
Journal:  Nature       Date:  1977-05-19       Impact factor: 49.962

3.  Binding interactions of lysergic acid diethylamide and related agents with dopamine receptors in the brain.

Authors:  D R Burt; I Creese; S H Snyder
Journal:  Mol Pharmacol       Date:  1976-07       Impact factor: 4.436

4.  Blood and urine levels of N,N-dimethyltryptamine following administration of psychoactive dosages to human subjects.

Authors:  J Kaplan; L R Mandel; R Stillman; R W Walker; W J VandenHeuvel; J C Gillin; R J Wyatt
Journal:  Psychopharmacologia       Date:  1974

5.  The effects of N,N-dimethyltryptamine on operant behavior in squirrel monkeys.

Authors:  J M Cole; W A Pieper
Journal:  Psychopharmacologia       Date:  1973-03-16

6.  Turning behavior of mice with unilateral 6-hydroxydopamine lesions in the striatum: effects of apomorphine, L-DOPA, amanthadine, amphetamine and other psychomotor stimulants.

Authors:  P F Von Voigtlander; K E Moore
Journal:  Neuropharmacology       Date:  1973-05       Impact factor: 5.250

7.  The biosynthesis of dimethyltryptamine in vivo.

Authors:  L R Mandel; R Prasad; B Lopez-Ramos; R W Walker
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1977-01

8.  Studies in vivo on the relationship between brain tryptophan, brain 5-HT synthesis and hyperactivity in rats treated with a monoamine oxidase inhibitor and L-tryptophan.

Authors:  D G Grahame-Smith
Journal:  J Neurochem       Date:  1971-06       Impact factor: 5.372

9.  Hallucinogenic indoleamines: Preferential action upon presynaptic serotonin receptors.

Authors:  G K Aghajanian; H J Hailgler
Journal:  Psychopharmacol Commun       Date:  1975

10.  The effects of putative 5-hydroxytryptamine antagonists on the behaviour produced by administration of tranylcypromine and L-tryptophan or tranylcypromine and L-DOPA to rats.

Authors:  J F Deakin; A R Green
Journal:  Br J Pharmacol       Date:  1978-10       Impact factor: 8.739

View more
  7 in total

1.  Effects of N, N-Dimethyltryptamine on Rat Behaviors Relevant to Anxiety and Depression.

Authors:  Lindsay P Cameron; Charlie J Benson; Lee E Dunlap; David E Olson
Journal:  ACS Chem Neurosci       Date:  2018-04-24       Impact factor: 4.418

Review 2.  A possibly sigma-1 receptor mediated role of dimethyltryptamine in tissue protection, regeneration, and immunity.

Authors:  Ede Frecska; Attila Szabo; Michael J Winkelman; Luis E Luna; Dennis J McKenna
Journal:  J Neural Transm (Vienna)       Date:  2013-04-26       Impact factor: 3.575

3.  The hallucinogen N,N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator.

Authors:  Dominique Fontanilla; Molly Johannessen; Abdol R Hajipour; Nicholas V Cozzi; Meyer B Jackson; Arnold E Ruoho
Journal:  Science       Date:  2009-02-13       Impact factor: 47.728

4.  Comparison of the discriminative stimulus effects of dimethyltryptamine with different classes of psychoactive compounds in rats.

Authors:  Michael B Gatch; Margaret A Rutledge; Theresa Carbonaro; Michael J Forster
Journal:  Psychopharmacology (Berl)       Date:  2009-03-14       Impact factor: 4.530

5.  Interaction of synthetic opioid metenkephalin peptide analogs, Lilly 127623 and FK 33-824 with indole hallucinogens: antagonism of N,N-dimethyltryptamine- and LSD-induced disruption of food-rewarded bar pressing behavior in the rat.

Authors:  D M Ruffing; E F Domino
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

Review 6.  Neuropharmacology of N,N-dimethyltryptamine.

Authors:  Theresa M Carbonaro; Michael B Gatch
Journal:  Brain Res Bull       Date:  2016-04-25       Impact factor: 4.077

7.  Effects of pargyline and SKF-525A on brain N,N-dimethyltryptamine concentrations and hyperactivity in mice.

Authors:  A Morinan; J G Collier
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.